Search company, investor...

Intrinsic Therapeutics

Founded Year



Unattributed - II | Alive

Total Raised


Last Raised

$5.91M | 2 mos ago

About Intrinsic Therapeutics

Intrinsic Therapeutics develops medical devices. It offers a device to close large defects in the annulus and therapies for soft-tissue injuries of the spine. Intrinsic Therapeutics was formerly known as MedGenesis. It was founded in 2000 and is based in Woburn, Massachusetts.

Headquarters Location

30 Commerce Way

Woburn, Massachusetts, 01801,

United States


Missing: Intrinsic Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Intrinsic Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Intrinsic Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Intrinsic Therapeutics is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,928 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Intrinsic Therapeutics Patents

Intrinsic Therapeutics has filed 38 patents.

The 3 most popular patent topics include:

  • Bones of the vertebral column
  • Bones of the thorax
  • Dosage forms
patents chart

Application Date

Grant Date


Related Topics




Bones of the vertebral column, Medical equipment, Dosage forms, Drug delivery devices, Implants (medicine)


Application Date


Grant Date



Related Topics

Bones of the vertebral column, Medical equipment, Dosage forms, Drug delivery devices, Implants (medicine)



Latest Intrinsic Therapeutics News

Synlogic appoints Michael Jensen as CFO

Mar 3, 2022

Synlogic (NASDAQ: SYBX ) has appointed  Michael Jensen as CFO. Mr. Jensen, most recently served as the CFO at Intrinsic Therapeutics, a commercial-stage medical device company focused on delivering treatments to improve surgical efficacy. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Intrinsic Therapeutics Frequently Asked Questions (FAQ)

  • When was Intrinsic Therapeutics founded?

    Intrinsic Therapeutics was founded in 2000.

  • Where is Intrinsic Therapeutics's headquarters?

    Intrinsic Therapeutics's headquarters is located at 30 Commerce Way, Woburn.

  • What is Intrinsic Therapeutics's latest funding round?

    Intrinsic Therapeutics's latest funding round is Unattributed - II.

  • How much did Intrinsic Therapeutics raise?

    Intrinsic Therapeutics raised a total of $274.58M.

  • Who are the investors of Intrinsic Therapeutics?

    Investors of Intrinsic Therapeutics include Questa Capital, Delos Capital, New Enterprise Associates, Epidarex Capital, Paycheck Protection Program and 10 more.

  • Who are Intrinsic Therapeutics's competitors?

    Competitors of Intrinsic Therapeutics include SynergEyes, MedShape, FzioMed, Mobius Therapeutics, Mercator MedSystems and 10 more.

Compare Intrinsic Therapeutics to Competitors

Proneuron Biotechnologies

Biopharmaceutical products for the of spinal cord injuries and other central nervous system disorders.


Haemechanics has developed a synthetic, hemostatic material capable of simultaneously inducing blood clotting and delivering therapeutics. The material is able to induce clotting as effectively as biologically based products, at a fraction of the price.


OrthoMimetics aiming to bring to market a line of products for the regenerative repair of cartilage, ligament and tendon injuries.

Matrix Genomics Logo
Matrix Genomics

aims to provide customized genetic assessments of inherited susceptibility to age-related disorders.

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

Vitreo Retinal Technologies

Vitreo Retinal Technologies, Inc. is developing therapeutics for the treatment of serious ocular diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.